Lancet 382, 158169
a combination of (i) an amount of at least one compound effective for agonizing a melanocortin-receptor selected from MC- 1 R and MC-4R, and (ii) an amount of at least one compound effective for inhibiting cAMP phosphodiesterase." Specific disclosures are only to PDE-3, -4, -7 or -8 inhibitors, and a number of specific diseases are disclosed (e.g., inflammatory bowel disease, rheumatoid arthritis, asthma, etc.), but not sexual dysfunction
Upper arm: The outer aspect of the upper arm may be used
When to seek urgent care: Severe or persistent nausea and vomiting leading to dehydration contact NHS 111 or your trial team Sudden, severe abdominal pain seek urgent medical attention Signs of a severe allergic reaction (anaphylaxis), including rash, swelling of the face, lips, or throat, or difficulty breathing call 999 immediately Upper right abdominal pain, fever, or jaundice seek medical attention Any new or worsening symptoms following an injection contact your trial team Reporting side effects: Patients and healthcare professionals are encouraged to report suspected adverse reactions via the MHRA Yellow Card Scheme at yellowcard.mhra.gov.uk or via the Yellow Card app
Early satiety from GLP-1 medications is described as feeling comfortably full after eating much smaller portions than usual, often accompanied by reduced interest in food and decreased cravings
Improved Metabolic Health: Beyond weight loss, these programs can improve blood sugar control and reduce risks associated with obesity, such as type 2 diabetes and cardiovascular disease
